Denmark · 
What does Novo Holdings invest in?
Novo Holdings invests most often at Series A and Series B (62% of the rounds on record), in sectors such as Fintechs, Regtech and Finserv.
Novo Holdings highlights
- 01
36 cheques in the last 12 months
- 02
Mostly Series A and Series B: 62% of its rounds
- 03
Sole investor in 12 rounds, median $54M
- 04
7 exits from the portfolio
What they do
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- FintechsRegtechFinserv
- Based in
- Hellerup, Denmark
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first203 appearances
- 2026
29 rounds
- Oct
- Oct
- Sept
- Sept
- Sept
- Sept
- Aug
- Jul
- Jul
- Jul
- Jun
- Jun
- Jun
- May
- May
- Apr
- Apr
- Apr
- Apr
- Apr
- Apr
- Apr
- Feb
- Feb
- Feb
- Jan
- Jan
- Jan
- Jan
- 2025
48 rounds
- Dec
- Dec
- Dec
- Nov
- Nov
- Nov
- Nov
- Oct
- Oct
- Oct
- Oct
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 43 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Funds they back
4 fund commitments on record
- Managers
- 3
Every fund on record that it has committed money to, and the managers who invest it.Source: fund news.
Managers it backs most
Most recent commitments
What they claim to have backed
From their own portfolio page (on their website)
0 of 1 we have independently watched raise
Novo Nordisk Foundation
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed7 in all
Alios BioPharmaBought by Johnson & Johnson$1.8BSept 2014
CellBiosciencesBought by Bio-TechneUndisclosedJun 2014
NeomendBought by C. R. Bard$140MOct 2012
Elevation PharmaceuticalsBought by Sunovion Pharmaceuticals$430MAug 2012
Synosia TherapeuticsBought by Biotie Therapies$122MJan 2011
Foldrx PharmaceuticalsBought by PfizerUndisclosedSept 2010
Gloucester PharmaceuticalsBought by Celgene$640MDec 2009
An exit counts when it came after the firm's first round in the company. From historical deal records.